IMMUNOLOGICAL MECHANISMS OF PSORIASIS PATHOGENESIS

About the author:	
Kutasevych Ya.F., Sokol O. A., Kondakova H. K.	
Heading	review	
Type of article	Scientific Article	
Annotation	The article presents literature data on the study of the content of pro- and 
anti-inflammatory cytokines in psoriasis and their relationship with the activity 
of the dermatological pathological process. Cytokines play one of the key roles 
in the development and maintenance of psoriatic lesions. Processes that are 
accompanied by pathological changes in lymphocytes, neutrophils, 
keratinocytes, endothelial and other cells in psoriasis are induced by the 
combined effects of many cytokines, chemokines, and other mediators of 
inflammation. It is possible that an imbalance in the system of pro- and 
anti-inflammatory cytokines of systemic and local origin may play a key role 
in this pathology.	
Tags	psoriasis, pathogenesis, cytokines	
Bibliography	1.	Belozorov A. P. Inflammosomy i ih rol’ v patologii(Inflammosomes and their 
role in  pathology) Vіsnik HNU іm. V. N. Karazіna. 2014; 21(1112): 25–30 [In Ukr.].
2.	Vozniak I. Ia., Syzon O. O. Analiz osoblyvostei nyzky tsytokinovykh ta 
imunomorfolohichnykh zmin u khvorykh na psoriaz(Analysis of features of a 
number of cytokine and immunomorphological changes in patients with psoriasis). 
Ukrainskyi zhurnal dermatolohii, venerolohii, kosmetolohii. 2016; 3(62): 9–15[
In Ukr.].
3.	Sarian E. I. Biomarkery psoriaza i komorbidnyh sostoyanij(Biomarkers of 
psoriasis and comorbid conditions). Dermatologiya i venerologiya. 2018; 2: 43–47
[In Ukr.].
4.	Khimion L. V., Boiko A. V. Tradytsiini faktory ryzyku ta interleikin‑10 u
 rozvytku  Zapalennia ta aterosklerozu v khvorykh na psoriatychnyi artryt
(Traditional risk factors and interleukin-10 in the development of inflammation and 
atherosclerosis in patients with psoriatic arthritis) Zdobutky klinichnoi i 
eksperymentalnoi medytsyny. 2019; Т. 4: 136–143. 
https://doi.org/10.11603/1811–2471.2019.v.i4.10814[In Ukr.].
5. Yihua Cai, Feng Xue, Chen Quan[et al.]. Aсritical role of the IL‑1β‑IL‑1R 
signaling pathway in skin inflammation and psoriasis pathogenesis. Journal of 
investigative dermatology. 2018. doi: 10.1016/j.jid.2018.07.025.
6. Kutwin M., Migdalska‑Sęk M., Brzeziańska‑Lasota E., Zelga P., 
Woęniacka A. An analysis of IL‑10, IL‑17A, IL‑17RA, IL‑23A and IL‑23R 
expression and their correlation with clinical course in patients with psoriasis. J. 
Clin. Med. 2021; 10 (24): 5834. https://doi.org/10.3390/jcm10245834.
7. M. A. Brown, J. H. Pierce, C. J. Watson[et al.]. B cell stimulatory factor-1 / 
Interleukin-4 mRNA is expressed by normal and transformed mast cells. Cell. 1987; 
50(5): 809–818.
8. Baliwag J., Barnes D.H, Johnston A. Cytokines in psoriasis. Cytokine. 2015; 73: 
342–350.
9. Baran W., Szepietowski J. C., Mazur G., Baran E. IL‑6 and IL‑10 promoter gene
 polymorphisms in psoriasis vulgaris. Acta Derm Venereol. 2008; 88(2): 113–116.
10. Bauernfeind F., Hornung V. Of inflammasomes and pathogens‑sensing of 
microbes by the inflammasome. EMBO Mol. Med. 2013; 5 (6): 814–826. 
doi: [10.1002/emmm.201201771].
11. Atreya R., Mudter J., Finotto S., Mullberg J. [et al.]. Blockade of interleukin-6 
trans signaling suppresses T‑cell resistance against apoptosis in chronic intestinal 
inflammation: evidence in Crohn’s disease and experimental colitis in vivo. Nat. Med. 
2000; 6: 583–588. doi:10.1038/75068.
12. Brunner T., Heusser C. H., Dahinden C. A. Human peripheral blood basophils 
primed by interleukin3 (IL-3) produce IL‑4 in response to immunoglobulin E receptor 
stimulation. J. Exp. Med. 1993; 177 (3): 605–611.
13. Capon F. The genetic basis of psoriasis. Int. J. Mol. Sci. 2017; 18: 2526. 
https://doi.org/10.3390/ijms18122526.
14. Christophers E., Metzler G., Röcken M. Bimodal immune activation in psoriasis. 
Br. J. Dermatol. 2014; 170(1): 59–65.
15. Cooney L. A., Towery K., Endres J., Fox D. A. Sensitivity and resistance to 
regulation by IL-4 during Th17 maturation. J Immunol. 2011; 187 (9): 4440–50. doi: 10.4049/jimmunol.1002860.
16. Chen Y. Yu, Y., Wang F. L., Sun J., Li H. J., Liu J. M. Cytokines interleukin4 (IL-4) 
and interleukin10 (IL-10) gene polymorphisms as potential host susceptibility factors 
in virus-induced  encephalitis. Med. Sci. Monit. 2017; 23.
17. Dombrowski Y., Peric M., Koglin S. [et al.]. Cytosolic DNA triggers inflammasome 
activation in keratinocytes in psoriatic lesions. Sci. Transl. Med. 2011; 3 (82): 82ra38. 
doi:[10.1126/scitranslmed.3002001].
18. Augustin M., Reich K., Glaeske G. [et al.]. Co‑morbidity and age‑related 
prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm. 
Venereol.2010; 90: 147–151. https://doi.org/10.2340/00015555–0770.
19. Corfe S. A., Paige C. J. The many roles of IL‑7 in B cell development; Mediator 
of survival, proliferation and differentiation. Seminars in Immunology. 2012; 24: 
198–208.
20. Cosmi L, Liotta F, Maggi E. Th17 and non‑classic Th1 cells in chronic 
inflammatory disorders: two sides of the same coin. Int Arch Allergy Immunol2014; 
164 (3): 171–7.
21. Gabay C. Interleukin‑6 and chronic inflammation. Arthritis research& therapy. 
2006; 8: 3.
22. Griffiths C. E. M., Armstrong A. W., Gudjonsson J. E., Barker J. N. W. N. Psoriasis. Lancet.
2021; 397: 1301–1315.
23. Gudjonsson J. E., Johnston A, Sigmundsdottir H, Valdimarsson H. 
Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol. 2004 Jan;135(1):
1–8. doi: 10.1111/j.1365–2249.2004.02310.x. PMID: 14678257; PMCID: PMC1808928.
24. Hahn M., Ghoreschi K. The role of IL‑4 in psoriasis. Exp. Rev. Clin. Immun. 2017; 
13(3): 171–173. doi.org/10.1080/1744666X.2017.1279054.
25. Hsu HC, Yang P, Wang J. Interleukin17‑producing T helper cells and interleukin17 or‑
chestrate autoreactive germinal center development in autoimmune BXD2 mice. 
Nat Immunol 2008; 9: 166–75.
26. Szabo S. K., Hammerberg C., Yoshida Y., Bata‑Csorgo Z. [et al.]. Identification 
And quantitation of interferon‑gamma producing T cells in psoriatic lesions: 
localization to both CD4+ and CD8+ subsets. J. Invest. Dermatol. 1998; 111 (6): 
1072–1078. doi: 10.1046/j.1523–1747.1998.00419.x. PMID: 9856819.
27. Onderdijk A. J., Baerveldt E. M., Kurek D., Kant M. [et al.]. IL-4 downregulates 
IL-1β and IL-6 and induces GATA3 in psoriatic epidermal cells: route of action of a 
Th2 cytokine. J Immunol. 2015;195 (4): 1744–1752. doi: 10.4049/jimmunol.1401740.
28. Mitchell R. E., Hassan M., Burton B. R., Britton G. [et al.]. IL-4 enhances IL-10 
Production in Th1 cells: implications for Th1 and Th2 regulation. Sci. Rep. 2017; 7 (1): 
11315. doi: 10.1038/s41598–017–11803‑y. PMID: 28900244; PMCID: PMC5595963.
29. Kaplanski G., Marin V., Montero‑Julian F., Mantovani A., Farnarier C. IL-6: 
a regulator of the transition from neutrophil to monocyte recruitment during
 inflammation. Trends Immunol. 2003; 24: 25–29. 
doi: 10.1016/S1471–4906(02)00013–3.
30. Goodman W. A., Levine A. D., Massari J. V., Sugiyama H. [et al.]. IL‑6 signaling
 in psoriasis prevents immune suppression by regulatory T cells. J. Immunol. 2009; 
183 (5): 3170–3176. 
doi: 10.4049/jimmunol.0803721. Epub2009 Jul31. PMID: 19648274; PMCID: 
PMC2903207.
31. McInnes I. B., Illei G. G., Danning C. L., Yarboro C. H. [et al.]. IL‑10 improves 
skin disease and modulates endothelial activation and leukocyte effector function in 
patients with psoriatic arthritis. J Immunol. 2001: 167 (7): 4075–4082. doi: https://doi.org/10.4049/jimmunol.167.7.4075.
32. Al‑Robaee A. A., Al‑Zolibani A. A., Al‑Shobili Y. A., Kazamel A. [et al.]. IL-10 
Implications in psoriasis. Int. J. Health Sci. 2008; 2 (1): 53–58. PMID: 21475472; 
PMCID: PMC3068725.
33. Asadullah K., Sterry W., Stephanek K., Jasulaitis D. [et al.]. IL-10 is a key cytokine 
in psoriasis. Proof of principle by IL‑10 therapy: a new therapeutic approach. J. Clin. 
Invest. 1998; 101 (4): 783–794. doi: 10.1172/JCI1476. PMID: 9466973; PMCID: 
PMC508626.
34. Prens E., Hegmans J., Lien R. C., Debets R. [et al.]. Increased expression of 
Interleukin-4 receptors on psoriatic epidermal cells. Am. J. Pathol. 1996; 148(5): 
1493–1502.
35. Neuner P., Urbanski A., Trautinger F., Möller A. [et al.]. Increased IL-6 production 
By monocytes and keratinocytes in patients with psoriasis. J. Invest. Dermatol.1991; 
97 (1): 27–33. doi: 10.1111/1523–1747.ep12477880. PMID: 2056189.
36. Szepietowski J. C., Bielicka E., Nockowski P., Noworolska A. Increased 
Interleukin-7 levels in the sera of psoriatic patients: lack of correlations with 
interleukin‑6 levels and disease intensity. Clin. Exp. Dermatol. 2000; 25 (8): 643–647.
 doi: 10.1046/j.1365–2230.2000.00727.x. PMID: 11167981.
37. Hochrein H., O’Keeffe M., Luft T., Vandenabeele S. [et al.].Interleukin(IL)-4 is a 
Major regulatory cytokine governing bioactive IL-12 production by mouse and human 
dendritic cells.J Exp. Med. 2000; 192 (6): 823–833. doi: 10.1084/jem.192.6.823.
38. Iversen L., Johansen C. Inflammasomes and inflammatory caspases in skin 
inflammation. Expert Rev. Mol. Diagn. 2008; 8: 697–705. http: 
dx.doi.org/10.1586/14737159.8.6.697.
39. Kimura A., NakaТ., KishimotoТ. IL‑6‑dependent and ‑independent pathways 
in the development of interleukin17‑producing T helper cells. Proc. Natl. Acad. Sci. 
USA. 2007; 104: 12099–12104.
40. Langley R. G.B., Krueger G. G., Griffiths C. E.M. Psoriasis: epidemiology, clinical 
features, and quality of life. Annals of the Rheumatic Diseases. 2005; 64: ii18‑ii23. 
http://dx.doi.org/10.1136/ard.2004.033217.
41. Latz E., Xiao T. S., Stutz A. Activation and regulation of the inflammasomes. Nat. 
Rev. Immunol. 2013; 13(6): 397–411.
42. Lopez‑Castejon G., Brough D. Understanding the mechanism of IL‑1beta 
secretion. Cytokine growth factor rev. 2011; 22 (189): e95.
43. Doherty T. A., Khorram N., Lund S. [et al.]. Lung type2 innate lymphoid cells 
express cysteinyl leukotriene receptor1, which regulates TH2 cytokine production. 
J. Allergy Clin. Immunol. 2013; 132 (1): 205–213.
44. Martinon F., Burns K., Tschopp J. The inflammasome: a molecular platform 
triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell. 
2002; 10(2): 417–426.
45. Mittal S. K., Roche P. A. Suppression of antigen presentation by IL-10. Curr.
Opin. Immunol. 2015; 34: 22–27. doi: 10.1016/j.coi.2014.12.009.
46. Mizutani H., Black R., Kupper T. S. Human keratinocytes produce but do not 
process pro-interleukin-1 (IL-1) beta. Different strategies of IL‑1 production and 
processing in monocytes and keratinocytes. J. Clin. Invest. 1991; 87: 1066e71.
47. Eyerich S., Onken, A. T. Weidinger S., Franke A. [et al.]. Mutual antagonism of 
T cells causing psoriasis and atopic eczema. N. Engl. J. Med. 2011;. 365 (3): 231–238.
 doi: 10.1056/NEJMoa1104200. PMID: 21774711.
48. Perera G. K., Meglio P. Di, Nestle F. O. Psoriasis. Annu. Rev. Pathol. 2012; 7: 
385–422. doi: 10.1146/annurev‑pathol‑011811–132448.
49. Heinrich P. C., Behrmann I., Haan S., Hermanns H. M. Principles of interleukin(IL)
-6-type cytokine signalling and its regulation. Biochem. J. 2003; 374 (Pt 1): 1–20. 
doi: 10.1042/BJ20030407. PMID: 12773095; PMCID: PMC1223585.
50. Galizia G., Orditura M., Romano C., Lieto E. [et al.].Prognostic significance of 
Circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. 
Clin. Immunol. 2002; 102 (2): 169–178. doi: 10.1006/clim.2001.5163. PMID: 
11846459.
51. Cataldi C., Mari N. L., Lozovoy M.B[et al.]. Proinflammatory and anti‑inflammatory
 cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors. 
Inflamm Res. 2019; 68: 557–567.
52. Liang Y., Sarkar M. K., Tsoi L. C., Gudjonsson J. E. Psoriasis: a mixed 
autoimmune and autoinflammatory disease. Curr. Opin. Immunol. 2017; 49: 1–8. 
https://doi.org/10.1016/j.coi.2017.07.007.
53. Zheng X., Wang Q., Luo Y., Lu W. [et al.].Seasonal variation of psoriasis and its 
impact in the therapeutic management: a retrospective study on chinese patients Clin. 
Cosmet. Investig. Dermatol. 2021; 14: 459–465. doi: 10.2147/CCID.S312556. PMID: 
34007198; PMCID: PMC8121268.
54. Zhang Q., Wang H. Y., Marzec M., Raghunath P. N. [et al.]. STAT3 and DNA 
methyltransferase1 mediated epigenetic silencing of SHP‑1 tyrosine phosphatase 
tumor suppressor gene in malignant T lymphocytes. Proc. Natl. Acad. Sci. USA.2005;
 102: 6948–6953.
55. Johansen C., Moeller K., Kragballe K., Iversen L. The activity of caspase-1 is i
Ncreased in lesional psoriatic epidermis. J. Invest. Dermatol. 2007; 127: 2857–2864. 
http://dx.doi.org/10.1038/sj.jid.5700922.
56. Uyemura K., Yamamura M., Fivenson D. F., Modlin R. L., Nickoloff B. J. The 
cytokine network in lesional and lesion‑free psoriatic skin is characterized by a T-
helper type1 cell-mediated response. J. Invest. Dermatol. 1993; 101 (5): 701–705. 
oi: 10.1111/1523–1747.ep12371679. 
PMID: 76938254541–4548. doi: 10.12659/msm.904364. PMID: 28935853; PMCID: 
PMC5683680.
57. Leung S., Liu X., Fang L., Chen X., Guo T., Zhang J. The cytokine milieu in the
 Interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease. 
Cell Mol Immunol. 2010; May;7(3):182–9. doi: 10.1038/cmi.2010.22. Epub2010 
Apr12. PMID: 20383174; PMCID: PMC4002916.
58. Yoshimoto T., Bendelac A., Watson C., Hu‑Li J., Paul W. E. Role of NK1.1+ T 
cells in a Th2 response and in immunoglobulin E production. Science.1995; 270 
(5243): 1845–1847. doi: 10.1126/science.270.5243.1845. PMID: 8525383.
59. Basavaraj K. H., Ashok N. M., Rashmi R., Praveen T. K. The role of drugs in the 
Induction and/or exacerbation of psoriasis. Int. J. Dermatol. 2010; 49: 1351–1361. 
https://doi.org/10.1111/j.1365–4632.2010.04570.x
60. Hamzavi M., Tadbir A. A., Rezvani G., Ashraf M. J. [et al.]. Tissue expression, 
serum and salivary levels of IL-10 in patients with head and neck squamous cell 
carcinoma. Asian. Pac. J. Cancer Prev. 2013; 14 (3): 1681–1685. 
doi: 10.7314/apjcp.2013.14.3.1681. PMID: 23679256.
61. Simpson E. L., Bieber T., Guttman‑Yassky E., Beck L. A. [et al.]Two phase3 
trials of dupilumab versus placebo in atopic dermatitis. N. Engl. J. Med.2016; 375 (24):
 2335–2348. doi: 10.1056/NEJMoa1610020. Epub2016 Sep30. PMID: 27690741.
62. Woo Y. R., Cho D. H., Park H. J. Molecular mechanisms, and management of a 
Cutaneous inflammatory disorder: psoriasis. Int. J. Mol. Sci.2017; 18 (12): 2684	
Publication of the article	«DERMATOLOGY AND VENEREOLOGY» №1-2(95-96), 2022 year, 7-13 pages,
	
DOI	DOI: 10.33743/2308-1066-2022-1-2-7-13